Upfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast Cancer

(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic HER2-positive breast cancer. The combination…

Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsbreastca/116216

Author :

Publish date : 2025-06-24 15:23:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Upfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast Cancer

Simpler Lung Cancer Screening Criteria May Still Maintain Diagnostic Efficiency

How Fast Is Too Fast for FDA Drug Review?

Related Posts

Adults With HIV Report Greater Satisfaction After Switching to Long-Acting ART

A Physician’s Guide to What’s Next

‘Reframing’ Cancer; Breastfeeding and Cancer; Liquid Biopsies: Are We There Yet?

Fake Botox suspected in dozens of poisoning cases

Ranching and farming have eroded almost all the soil in the Alps

MHRA Approves UK’s First Nasal Spray for Anaphylaxis

Adults With HIV Report Greater Satisfaction After Switching to Long-Acting ART

A Physician’s Guide to What’s Next

‘Reframing’ Cancer; Breastfeeding and Cancer; Liquid Biopsies: Are We There Yet?

Fake Botox suspected in dozens of poisoning cases

Ranching and farming have eroded almost all the soil in the Alps

MHRA Approves UK’s First Nasal Spray for Anaphylaxis

Inhaled Sedative Safe, Effective for Kids on Mechanical Ventilation

As Past USPSTF Chairs, We Fear for the Future of the Task Force

Categories

Archives